Increasing both the number of shares and share price, iTeos Therapeutics has raised more than $201m in an offering that provided an exit to UCL and Ludwig Institute.
iTeos Therapeutics, a US-based immuno-oncology drug spinout of Université catholique de Louvain (UCL) and Ludwig Institute for Cancer Research, raised more than $201m in a listing on Friday.
The company priced its shares at $19, above its previous target of $18, and upped the number of shares by approximately 350,000 to 10.58 million. It has listed on the Nasdaq Global Market using the ticker symbol ITOS.
Founded in 2011, iTeos is developing immunotherapies aimed at a wide range…
